Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 10
1997 7
1998 26
1999 24
2000 29
2001 28
2002 30
2003 36
2004 66
2005 65
2006 55
2007 93
2008 67
2009 77
2010 124
2011 150
2012 176
2013 150
2014 203
2015 212
2016 234
2017 230
2018 209
2019 195
2020 228
2021 212
2022 200
2023 169
2024 71

Text availability

Article attribute

Article type

Publication date

Search Results

2,913 results

Results by year

Filters applied: . Clear all
Page 1
Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.
Thomas K, Proschmann U, Ziemssen T. Thomas K, et al. Expert Opin Pharmacother. 2017 Oct;18(15):1649-1660. doi: 10.1080/14656566.2017.1373093. Epub 2017 Sep 4. Expert Opin Pharmacother. 2017. PMID: 28844164 Review.
Fingolimod was the first oral and the first in class disease modifying treatment in multiple sclerosis that acts as sphingosine-1-phospathe receptor agonist. ...Expert opinion: There is an extensive long-term experience on fingolimod use in clinical practice demonst …
Fingolimod was the first oral and the first in class disease modifying treatment in multiple sclerosis that acts as sphingosine-1-pho …
Pregnancy and multiple sclerosis: an update.
Varytė G, Arlauskienė A, Ramašauskaitė D. Varytė G, et al. Curr Opin Obstet Gynecol. 2021 Oct 1;33(5):378-383. doi: 10.1097/GCO.0000000000000731. Curr Opin Obstet Gynecol. 2021. PMID: 34310364 Free PMC article. Review.
Natalizumab may also be continued until 34 weeks of pregnancy for patients requiring persisting treatment. Drugs with a known potential of teratogenicity such as fingolimod or teriflunomide should be avoided and recommended wash-out times for medications such as cladribine …
Natalizumab may also be continued until 34 weeks of pregnancy for patients requiring persisting treatment. Drugs with a known potential of t …
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
McGinley MP, Cohen JA. McGinley MP, et al. Lancet. 2021 Sep 25;398(10306):1184-1194. doi: 10.1016/S0140-6736(21)00244-0. Epub 2021 Jun 24. Lancet. 2021. PMID: 34175020 Review.
The reduction in circulating lymphocytes presumably limits inflammatory cell migration into the CNS. Four S1PR modulators (fingolimod, siponimod, ozanimod, and ponesimod) have regulatory approval for multiple sclerosis. ...
The reduction in circulating lymphocytes presumably limits inflammatory cell migration into the CNS. Four S1PR modulators (fingolimod …
Lymph-Node-Targeted Drug Delivery for Effective Immunomodulation to Prolong the Long-Term Survival After Heart Transplantation.
Che YJ, Ren XH, Wang ZW, Wu Q, Xing K, Zhang M, Xu C, Han D, Yuan S, Zheng SH, Chen YY, Liao XR, Shi F, Zhong XH, Cai X, Cheng SX. Che YJ, et al. Adv Mater. 2023 Apr;35(16):e2207227. doi: 10.1002/adma.202207227. Epub 2022 Dec 22. Adv Mater. 2023. PMID: 36314402
The targeting delivery system can dramatically enhance accumulation of the loaded immunosuppressant, fingolimod hydrochloride (FTY720), in draining lymph nodes (dLNs) for inducing powerful immune suppression. ...
The targeting delivery system can dramatically enhance accumulation of the loaded immunosuppressant, fingolimod hydrochloride …
Fingolimod: therapeutic mechanisms and ocular adverse effects.
Mandal P, Gupta A, Fusi-Rubiano W, Keane PA, Yang Y. Mandal P, et al. Eye (Lond). 2017 Feb;31(2):232-240. doi: 10.1038/eye.2016.258. Epub 2016 Nov 25. Eye (Lond). 2017. PMID: 27886183 Free PMC article. Review.
Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). ...Fingolimod-associated macular oedema (FAME) is the most common ocular side effect but retinal haemorrhages and retinal vein occlusion can occur. . …
Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). ...Fingolimod …
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Bravo GÁ, Cedeño RR, Casadevall MP, Ramió-Torrentà L. Bravo GÁ, et al. Cells. 2022 Jun 29;11(13):2058. doi: 10.3390/cells11132058. Cells. 2022. PMID: 35805142 Free PMC article. Review.
Modulation on S1P is an interesting target for the treatment of various autoimmune disorders. Improved understanding of the mechanism of action of fingolimod has allowed the development of the more selective second-generation S1PR modulators. ...The understanding of S1PR1' …
Modulation on S1P is an interesting target for the treatment of various autoimmune disorders. Improved understanding of the mechanism of act …
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.
Tsai HC, Han MH. Tsai HC, et al. Drugs. 2016 Jul;76(11):1067-79. doi: 10.1007/s40265-016-0603-2. Drugs. 2016. PMID: 27318702 Review.
However, the full extent of its involvement in the pathogenesis of autoimmune diseases is not well understood. FTY720 (fingolimod), a non-selective S1PR modulator, significantly decreased annualized relapse rates in relapsing-remitting multiple sclerosis (MS). ...
However, the full extent of its involvement in the pathogenesis of autoimmune diseases is not well understood. FTY720 (fingolimod), a …
Very-long-chain fatty acids induce glial-derived sphingosine-1-phosphate synthesis, secretion, and neuroinflammation.
Chung HL, Ye Q, Park YJ, Zuo Z, Mok JW, Kanca O, Tattikota SG, Lu S, Perrimon N, Lee HK, Bellen HJ. Chung HL, et al. Cell Metab. 2023 May 2;35(5):855-874.e5. doi: 10.1016/j.cmet.2023.03.022. Epub 2023 Apr 20. Cell Metab. 2023. PMID: 37084732 Free PMC article.
Suppressing the function of S1P in fly glia or neurons, or administration of Fingolimod, an S1P receptor antagonist, strongly attenuates the phenotypes caused by excess VLCFAs. ...Indeed, reducing VLCFA with bezafibrate ameliorates the phenotypes. Moreover, simultaneous us …
Suppressing the function of S1P in fly glia or neurons, or administration of Fingolimod, an S1P receptor antagonist, strongly attenua …
Fingolimod hydrochloride gel shows promising therapeutic effects in a mouse model of atopic dermatitis.
Tamakuwala M, Ratna W, Joshi A, Stagni G. Tamakuwala M, et al. J Pharm Pharmacol. 2016 Oct;68(10):1268-77. doi: 10.1111/jphp.12588. Epub 2016 Jul 27. J Pharm Pharmacol. 2016. PMID: 27465785
OBJECTIVES: To assess the efficacy of topically applied 2% hydroxypropyl cellulose gels containing 0.5% fingolimod hydrochloride (FNGL) with or without 6% colloidal oatmeal in an in vivo model of atopic dermatitis (AD). ...
OBJECTIVES: To assess the efficacy of topically applied 2% hydroxypropyl cellulose gels containing 0.5% fingolimod hydrochloride …
Fingolimod for relapsing-remitting multiple sclerosis.
La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G. La Mantia L, et al. Cochrane Database Syst Rev. 2016 Apr 19;4(4):CD009371. doi: 10.1002/14651858.CD009371.pub2. Cochrane Database Syst Rev. 2016. PMID: 27091121 Free PMC article. Review.
BACKGROUND: Fingolimod was approved in 2010 for the treatment of patients with the relapsing-remitting (RR) form of multiple sclerosis (MS). ...The risk of fingolimod discontinuation was significantly higher compared to placebo for the dose 1.25 mg at 24 months (RR …
BACKGROUND: Fingolimod was approved in 2010 for the treatment of patients with the relapsing-remitting (RR) form of multiple sclerosi …
2,913 results